Orion's darolutamide plus standard therapy cuts metastasis or death risk 58% in prostate cancer trial

• Orion’s darolutamide reduced the risk of metastasis or death in the Phase 3 DASL-HiCaP trial involving prostate cancer patients at high recurrence risk.
• The drug improved outcomes versus placebo when added to androgen deprivation therapy and radiation therapy; it is not approved for this setting.
• Results will be presented today at the European Society for Medical Oncology Congress 2026.
• The safety profile was consistent with previous studies, though severe adverse events were more frequent with darolutamide; overall survival follow-up continues.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orion Oyj published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610240235PRIMZONEFULLFEED1001279630) on October 24, 2026, and is solely responsible for the information contained therein.